-
1
-
-
84876149257
-
Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence
-
K.Mohd-Hanafiah, J.Groeger, A.Flaxman, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–1342.
-
(2013)
Hepatology
, vol.57
, pp. 1333-1342
-
-
Mohd-Hanafiah, K.1
Groeger, J.2
Flaxman, A.3
-
2
-
-
84921060015
-
Global distribution and prevalence of hepatitis C virus genotypes
-
J.Messina, I.Humphreys, A.Flaxman, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77–87.
-
(2015)
Hepatology
, vol.61
, pp. 77-87
-
-
Messina, J.1
Humphreys, I.2
Flaxman, A.3
-
3
-
-
84914150658
-
Global epidemiology and genotype distribution of the hepatitis C virus infection
-
This manuscript is the first to highlight globally that seroprevalence does not reflect viremia, and that estimates of chronic hepatitis C must rely better on HCV-RNA instead of HCV antibodies since 30% of seroreactive persons are in fact cured, so far mostly spontaneously
-
E.Gower, C.Estes, S.Blach, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(suppl):45–57.• This manuscript is the first to highlight globally that seroprevalence does not reflect viremia, and that estimates of chronic hepatitis C must rely better on HCV-RNA instead of HCV antibodies since 30% of seroreactive persons are in fact cured, so far mostly spontaneously.
-
(2014)
J Hepatol
, vol.61
, pp. 45-57
-
-
Gower, E.1
Estes, C.2
Blach, S.3
-
4
-
-
84920265713
-
Estimates on HCV disease burden worldwide - filling the gaps
-
H.Wedemeyer, G.Dore, J.Ward Estimates on HCV disease burden worldwide - filling the gaps. J Viral Hepat. 2015;22(suppl 1):1–5.
-
(2015)
J Viral Hepat
, vol.22
, pp. 1-5
-
-
Wedemeyer, H.1
Dore, G.2
Ward, J.3
-
5
-
-
84975279936
-
Hepatitis C virus seroprevalence in adults in Africa: a systematic review and meta-analysis
-
Forthcoming
-
J.Riou, M.Aït-Ahmed, A.Blake, et al. Hepatitis C virus seroprevalence in adults in Africa: a systematic review and meta-analysis. J Viral Hepat. Forthcoming.
-
J Viral Hepat
-
-
Riou, J.1
Aït-Ahmed, M.2
Blake, A.3
-
6
-
-
84894880765
-
Evaluation of liver disease progression in the German Hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection
-
M.Wiese, J.Fisher, M.Lobermann, et al. Evaluation of liver disease progression in the German Hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology. 2014;59:49–57.
-
(2014)
Hepatology
, vol.59
, pp. 49-57
-
-
Wiese, M.1
Fisher, J.2
Lobermann, M.3
-
8
-
-
84871055775
-
A comparative risk assessment of burden of disease and injury attributable to 67 risk factor and risk factors cluster in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
-
S.Lim, T.Vos, A.Flaxman, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factor and risk factors cluster in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–2260.
-
(2012)
Lancet
, vol.380
, pp. 2224-2260
-
-
Lim, S.1
Vos, T.2
Flaxman, A.3
-
9
-
-
84931560807
-
Recommendations on treatment of hepatitis C 2015
-
EASL. Recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236.
-
(2015)
J Hepatol
, vol.63
, pp. 199-236
-
-
-
11
-
-
84879420038
-
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
-
R.Bartenschlager, V.Lohmann, F.Penin. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol. 2013;11:482–496.
-
(2013)
Nat Rev Microbiol
, vol.11
, pp. 482-496
-
-
Bartenschlager, R.1
Lohmann, V.2
Penin, F.3
-
12
-
-
84902439547
-
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus free world?
-
I.Gentile, A.Buonomo, E.Zappulo, et al. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus free world? Expert Rev Anti Infect Ther. 2014;12:763–773.
-
(2014)
Expert Rev Anti Infect Ther
, vol.12
, pp. 763-773
-
-
Gentile, I.1
Buonomo, A.2
Zappulo, E.3
-
13
-
-
84898990930
-
New hepatitis C therapies: the toolbox, strategies, and challenges
-
This is an updated review on clinical virology of HCV with special focus on therapeutic implications of resistance-associated variants and HCV genotype diversity
-
J.M.Pawlotsky. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014;146:1176–1192.• This is an updated review on clinical virology of HCV with special focus on therapeutic implications of resistance-associated variants and HCV genotype diversity.
-
(2014)
Gastroenterology
, vol.146
, pp. 1176-1192
-
-
Pawlotsky, J.M.1
-
14
-
-
84929054425
-
Continued progress against hepatitis C infection
-
H.Convjeevaram. Continued progress against hepatitis C infection. JAMA. 2015;313:1716–1717.
-
(2015)
JAMA
, vol.313
, pp. 1716-1717
-
-
Convjeevaram, H.1
-
15
-
-
84944390503
-
HCV treatment: is it possible to cure all HCV patients?
-
A.Muir, S.Naggie. HCV treatment: is it possible to cure all HCV patients? Clin Gastroenterol Hepatol. 2015;13:2166–2172.
-
(2015)
Clin Gastroenterol Hepatol
, vol.13
, pp. 2166-2172
-
-
Muir, A.1
Naggie, S.2
-
16
-
-
84946595410
-
Bradyarrhythmias associated with sofosbuvir treatment
-
This is the first and most complete report of cardiac dysfunction using sofosbuvir
-
H.Fontaine, D.Duboc, S.Pol. Bradyarrhythmias associated with sofosbuvir treatment. N Engl J Med. 2015;373:1886–1888.• This is the first and most complete report of cardiac dysfunction using sofosbuvir.
-
(2015)
N Engl J Med
, vol.373
, pp. 1886-1888
-
-
Fontaine, H.1
Duboc, D.2
Pol, S.3
-
17
-
-
84938201899
-
Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C
-
T.Ahmad, P.Yin, J.Saffitz, et al. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology. 2015;62:409–416.
-
(2015)
Hepatology
, vol.62
, pp. 409-416
-
-
Ahmad, T.1
Yin, P.2
Saffitz, J.3
-
18
-
-
84951304878
-
Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use
-
J.Dyson, J.Hutchinson, L.Harrison, et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol. 2016;64:234–238.
-
(2016)
J Hepatol
, vol.64
, pp. 234-238
-
-
Dyson, J.1
Hutchinson, J.2
Harrison, L.3
-
19
-
-
84939829307
-
Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child–Pugh B compensated cirrhosis
-
Forthcoming
-
V.Soriano, P.Barreiro, C.De Mendoza, et al. Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child–Pugh B compensated cirrhosis. Antivir Ther. Forthcoming.
-
Antivir Ther
-
-
Soriano, V.1
Barreiro, P.2
De Mendoza, C.3
-
20
-
-
84975296572
-
Hypoglycemia in a diabetic patient during hepatitis C therapy
-
Forthcoming
-
V.Soriano, P.Barreiro, C.De Mendoza. Hypoglycemia in a diabetic patient during hepatitis C therapy. Hepatology. Forthcoming.
-
Hepatology
-
-
Soriano, V.1
Barreiro, P.2
De Mendoza, C.3
-
21
-
-
84940591343
-
Serious pulmonary toxicity secondary to novel hepatitis C antiviral therapy in a liver transplant recipient
-
R.Helmers, T.Byme, L.Wesselius, et al. Serious pulmonary toxicity secondary to novel hepatitis C antiviral therapy in a liver transplant recipient. Mayo Clin Proc. 2015;90:1294–1297.
-
(2015)
Mayo Clin Proc
, vol.90
, pp. 1294-1297
-
-
Helmers, R.1
Byme, T.2
Wesselius, L.3
-
22
-
-
84975315174
-
Safety and tolerability of direct-acting antiviral agents in the new era of hepatitis C therapy
-
Forthcoming
-
D.Banerjee, K.Reddy. Safety and tolerability of direct-acting antiviral agents in the new era of hepatitis C therapy. Aliment Pharmacol Therap. Forthcoming.
-
Aliment Pharmacol Therap
-
-
Banerjee, D.1
Reddy, K.2
-
23
-
-
84954399628
-
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
-
This review updates current knowledge and therapeutic implications of HCV resistance-associated variants
-
C.Sarrazin. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486–504.•• This review updates current knowledge and therapeutic implications of HCV resistance-associated variants.
-
(2016)
J Hepatol
, vol.64
, pp. 486-504
-
-
Sarrazin, C.1
-
24
-
-
84932613679
-
Difficult-to-cure populations with chronic hepatitis C: vanishing in the direct-acting antiviral era?
-
N.Terrault. Difficult-to-cure populations with chronic hepatitis C: vanishing in the direct-acting antiviral era? Hepatology. 2015;62:4–7.
-
(2015)
Hepatology
, vol.62
, pp. 4-7
-
-
Terrault, N.1
-
25
-
-
84941563178
-
Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C
-
P.Barreiro, P.Labarga, J.V.Fernandez-Montero, et al. Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C. J Clin Virol. 2015;71:63–66.
-
(2015)
J Clin Virol
, vol.71
, pp. 63-66
-
-
Barreiro, P.1
Labarga, P.2
Fernandez-Montero, J.V.3
-
26
-
-
84957438363
-
New hepatitis C therapies for special patient populations
-
This review updates the characteristics of patient populations that challenge the most the success of DAA combinations
-
V.Soriano, P.Labarga, C.De Mendoza, et al. New hepatitis C therapies for special patient populations. Exp Opin Pharmacother. 2016;17:217–229.• This review updates the characteristics of patient populations that challenge the most the success of DAA combinations.
-
(2016)
Exp Opin Pharmacother
, vol.17
, pp. 217-229
-
-
Soriano, V.1
Labarga, P.2
De Mendoza, C.3
-
27
-
-
84963736042
-
Comprehensive screening for naturally-occurring hepatitis C virus resistance to direct-acting antivirals in the NS3, NS5A and NS5B genes in worldwide isolates from viral genotypes 1-6
-
Forthcoming
-
J.Patiño-Galindo, K.Salvatierra, F.González-Candelas, et al. Comprehensive screening for naturally-occurring hepatitis C virus resistance to direct-acting antivirals in the NS3, NS5A and NS5B genes in worldwide isolates from viral genotypes 1-6. Antimicrob Agents Chemother. Forthcoming.
-
Antimicrob Agents Chemother
-
-
Patiño-Galindo, J.1
Salvatierra, K.2
González-Candelas, F.3
-
28
-
-
79959401302
-
Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV coinfected patients
-
A.Treviño, C.De Mendoza, P.Parra, et al. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV coinfected patients. Antiviral Ther. 2011;16:413–416.
-
(2011)
Antiviral Ther
, vol.16
, pp. 413-416
-
-
Treviño, A.1
De Mendoza, C.2
Parra, P.3
-
29
-
-
84975279902
-
Baseline prevalence and emergence of protease inhibitors resistance mutations following treatment in chronic HCV genotype 1 infected individuals
-
Forthcoming
-
L.Nguyen, E.Gray, J.Dean, et al. Baseline prevalence and emergence of protease inhibitors resistance mutations following treatment in chronic HCV genotype 1 infected individuals. Antivir Ther. Forthcoming.
-
Antivir Ther
-
-
Nguyen, L.1
Gray, E.2
Dean, J.3
-
30
-
-
84922318694
-
Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region
-
C.Sarrazin, E.Lathouwers, M.Peeters, et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antivir Res. 2015;116:10–16.
-
(2015)
Antivir Res
, vol.116
, pp. 10-16
-
-
Sarrazin, C.1
Lathouwers, E.2
Peeters, M.3
-
31
-
-
84903701056
-
Update on hepatitis C virus resistance to direct-acting antiviral agents
-
E.Poveda, D.Wyles, A.Mena, et al. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antivir Res. 2014;108:181–191.
-
(2014)
Antivir Res
, vol.108
, pp. 181-191
-
-
Poveda, E.1
Wyles, D.2
Mena, A.3
-
32
-
-
80055075318
-
NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5
-
S.Vallet, F.Viron, C.Henquell, et al. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Antivir Ther. 2011;16:1093–1102.
-
(2011)
Antivir Ther
, vol.16
, pp. 1093-1102
-
-
Vallet, S.1
Viron, F.2
Henquell, C.3
-
33
-
-
84873041135
-
Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment
-
D.Bartels, J.Sullivan, E.Zhang, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol. 2013;87:1544–1553.
-
(2013)
J Virol
, vol.87
, pp. 1544-1553
-
-
Bartels, D.1
Sullivan, J.2
Zhang, E.3
-
34
-
-
84858415895
-
Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, and NS5A inhibitor
-
Z.Plaza, V.Soriano, E.Vispo, et al. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, and NS5A inhibitor. Antivir Ther. 2012;17:921–926.
-
(2012)
Antivir Ther
, vol.17
, pp. 921-926
-
-
Plaza, Z.1
Soriano, V.2
Vispo, E.3
-
35
-
-
84875804486
-
Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors
-
D.Hernandez, N.Zhou, J.Ueland, et al. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol. 2013;57:13–18.
-
(2013)
J Clin Virol
, vol.57
, pp. 13-18
-
-
Hernandez, D.1
Zhou, N.2
Ueland, J.3
-
36
-
-
84975315288
-
Naturally occurring HCV NS5A/B inhibitor resistance-associated mutations to direct-acting antivirals
-
Forthcoming
-
L.Nguyen, N.Hall, D.Sheerin, et al. Naturally occurring HCV NS5A/B inhibitor resistance-associated mutations to direct-acting antivirals. Antivir Ther. Forthcoming.
-
Antivir Ther
-
-
Nguyen, L.1
Hall, N.2
Sheerin, D.3
-
37
-
-
84975315291
-
Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data
-
Forthcoming
-
Z.Chen, H.Li, H.Ren, et al. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. Sci Rep. Forthcoming.
-
Sci Rep
-
-
Chen, Z.1
Li, H.2
Ren, H.3
-
38
-
-
58149388300
-
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients
-
T.Kuntzen, J.Timm, A.Berical, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology. 2008;48:1769–1778.
-
(2008)
Hepatology
, vol.48
, pp. 1769-1778
-
-
Kuntzen, T.1
Timm, J.2
Berical, A.3
-
39
-
-
84898645159
-
Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors
-
V.Di Maio, V.Cento, C.Mirabelli, et al. Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors. Antimicrob Agents Chemother. 2014;58:2781–2797.
-
(2014)
Antimicrob Agents Chemother
, vol.58
, pp. 2781-2797
-
-
Di Maio, V.1
Cento, V.2
Mirabelli, C.3
-
40
-
-
84873604286
-
Antiviral resistance and the future landscape of hepatitis C virus infection therapy
-
D.Wyles. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis. 2013;207(suppl 1):33–39.
-
(2013)
J Infect Dis
, vol.207
, pp. 33-39
-
-
Wyles, D.1
-
41
-
-
84927798764
-
Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies
-
O.Lenz, T.Verbinnen, B.Fevery, et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. J Hepatol. 2015;62:1008–1014.
-
(2015)
J Hepatol
, vol.62
, pp. 1008-1014
-
-
Lenz, O.1
Verbinnen, T.2
Fevery, B.3
-
42
-
-
84940942461
-
Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir and dasabuvir
-
P.Krishnan, R.Tripathi, G.Schnell, et al. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir and dasabuvir. Antimicrob Agents Chemother. 2015;59:5445–5454.
-
(2015)
Antimicrob Agents Chemother
, vol.59
, pp. 5445-5454
-
-
Krishnan, P.1
Tripathi, R.2
Schnell, G.3
-
43
-
-
84939260843
-
Resistance analysis of virologic failure in hepatitis C genotype 1 infected patients treated with grazoprevir/elbasvir ± ribavirin: the C-WORTHY study
-
S.Black, I.Pak, P.Ingravallo, et al. Resistance analysis of virologic failure in hepatitis C genotype 1 infected patients treated with grazoprevir/elbasvir ± ribavirin: the C-WORTHY study. J Hepatol. 2015;62(suppl):677–678.
-
(2015)
J Hepatol
, vol.62
, pp. 677-678
-
-
Black, S.1
Pak, I.2
Ingravallo, P.3
-
44
-
-
84921276609
-
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subject treated with sofosbuvir in phase 2 and 3 clinical trials
-
E.Svarovskaia, H.Dvory-Sobol, H.Parkin, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subject treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis. 2014;59:1666–1674.
-
(2014)
Clin Infect Dis
, vol.59
, pp. 1666-1674
-
-
Svarovskaia, E.1
Dvory-Sobol, H.2
Parkin, H.3
-
45
-
-
84943815570
-
Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy
-
C.Hedskog, H.Dvory-Sobol, V.Gontcharova, et al. Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy. J Viral Hepat. 2015;22:871–881.
-
(2015)
J Viral Hepat
, vol.22
, pp. 871-881
-
-
Hedskog, C.1
Dvory-Sobol, H.2
Gontcharova, V.3
-
46
-
-
84920945807
-
Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir
-
E.Donaldson, P.Harrington, J.O´Rear, et al. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology. 2015;61:56–65.
-
(2015)
Hepatology
, vol.61
, pp. 56-65
-
-
Donaldson, E.1
Harrington, P.2
O´Rear, J.3
-
47
-
-
84941917709
-
Hepatitis C virus drug resistance-associated substitutions: state of the art summary
-
This position paper records the most relevant information on HCV drug resistance
-
E.Lontok, P.Harrington, A.Howe, et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology. 2015;62:1623–1632.•• This position paper records the most relevant information on HCV drug resistance.
-
(2015)
Hepatology
, vol.62
, pp. 1623-1632
-
-
Lontok, E.1
Harrington, P.2
Howe, A.3
-
48
-
-
84964762303
-
Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r, ombitasvir- and dasabuvir based-regimens
-
P.Krishnan, R.Tripathi, G.Schnell, et al. Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r, ombitasvir- and dasabuvir based-regimens. J Hepatol. 2015;62:1008–1014.
-
(2015)
J Hepatol
, vol.62
, pp. 1008-1014
-
-
Krishnan, P.1
Tripathi, R.2
Schnell, G.3
-
49
-
-
84879683134
-
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials
-
J.Sullivan, S.De Meyer, D.Bartels, et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis. 2013;57:221–229.
-
(2013)
Clin Infect Dis
, vol.57
, pp. 221-229
-
-
Sullivan, J.1
De Meyer, S.2
Bartels, D.3
-
50
-
-
84918577537
-
Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real world experience
-
D.Jensen, J.O´Leary, P.Pockros, et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real world experience. Hepatology. 2014;60(supp l):219A.
-
(2014)
Hepatology
, vol.60
, pp. 219
-
-
Jensen, D.1
O´Leary, J.2
Pockros, P.3
-
51
-
-
84923037769
-
Evaluation of sofosbuvir and simeprevir –based regimens in the TRIO network: academic and community treatment of a real world, heterogeneous population
-
D.Dieterich, B.Bacon, S.Flamm, et al. Evaluation of sofosbuvir and simeprevir –based regimens in the TRIO network: academic and community treatment of a real world, heterogeneous population. Hepatology. 2014;60(suppl):220A.
-
(2014)
Hepatology
, vol.60
, pp. 220
-
-
Dieterich, D.1
Bacon, B.2
Flamm, S.3
-
53
-
-
84946945495
-
Management of direct antiviral agent failures
-
M.Buti, M.Riveiro-Barciela, R.Esteban. Management of direct antiviral agent failures. J Hepatol. 2015;63:1511–1522.
-
(2015)
J Hepatol
, vol.63
, pp. 1511-1522
-
-
Buti, M.1
Riveiro-Barciela, M.2
Esteban, R.3
-
54
-
-
84900339263
-
ION-1 Investigators. Ledipasvir and sofosbuvir for untreated genotype 1 infection
-
N.Afdhal, S.Zeuzem, P.Kwo, et al. ION-1 Investigators. Ledipasvir and sofosbuvir for untreated genotype 1 infection. N Engl J Med. 2014;370:1889–1898.
-
(2014)
N Engl J Med
, vol.370
, pp. 1889-1898
-
-
Afdhal, N.1
Zeuzem, S.2
Kwo, P.3
-
55
-
-
84898669547
-
ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
-
N.Afdhal, K.Reddy, D.Nelson, et al. ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl Med. 2014;370:1483–1493.
-
(2014)
N Engl Med
, vol.370
, pp. 1483-1493
-
-
Afdhal, N.1
Reddy, K.2
Nelson, D.3
-
56
-
-
84948705255
-
Sofosbuvir with velpatasvir in treatment-naive non-cirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial
-
G.Everson, W.Towner, M.Davis, et al. Sofosbuvir with velpatasvir in treatment-naive non-cirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015;163:818–826.
-
(2015)
Ann Intern Med
, vol.163
, pp. 818-826
-
-
Everson, G.1
Towner, W.2
Davis, M.3
-
57
-
-
84856159009
-
Preliminary study of two antiviral agents for hepatitis C genotype 1
-
A.Lok, D.Gardiner, E.Lawitz, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366:216–224.
-
(2012)
N Engl J Med
, vol.366
, pp. 216-224
-
-
Lok, A.1
Gardiner, D.2
Lawitz, E.3
-
58
-
-
84906814530
-
All oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
-
M.Manns, S.Pol, I.Jacobson, et al. All oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384:1597–1605.
-
(2014)
Lancet
, vol.384
, pp. 1597-1605
-
-
Manns, M.1
Pol, S.2
Jacobson, I.3
-
59
-
-
84894621765
-
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
-
E.Lawitz, F.Poordad, P.Pangs, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383:515–523.
-
(2014)
Lancet
, vol.383
, pp. 515-523
-
-
Lawitz, E.1
Poordad, F.2
Pangs, P.3
-
60
-
-
84892619580
-
Daclatasvir plus sosfosbuvir for previously treated or untreated chronic HCV infection
-
M.Sulkowski, D.Gardiner, M.Rodriguez-Torres, et al. Daclatasvir plus sosfosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–221.
-
(2014)
N Engl J Med
, vol.370
, pp. 211-221
-
-
Sulkowski, M.1
Gardiner, D.2
Rodriguez-Torres, M.3
-
61
-
-
84925364974
-
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study
-
D.Nelson, J.Cooper, J.Lalezari, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study. Hepatology. 2015;61:1127–1135.
-
(2015)
Hepatology
, vol.61
, pp. 1127-1135
-
-
Nelson, D.1
Cooper, J.2
Lalezari, J.3
-
62
-
-
84975301024
-
Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection
-
Forthcoming
-
C.Landaverde, J.Wells, R.Hamner, et al. Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection. Expert Rev Gastroenterol Hepatol. Forthcoming.
-
Expert Rev Gastroenterol Hepatol
-
-
Landaverde, C.1
Wells, J.2
Hamner, R.3
-
63
-
-
84939833091
-
Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1
-
D.Wyles, P.Ruane, M.Sulkowski, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:714–725.
-
(2015)
N Engl J Med
, vol.373
, pp. 714-725
-
-
Wyles, D.1
Ruane, P.2
Sulkowski, M.3
-
64
-
-
84925607745
-
Virological response after 6 week triple drug regimens for hepatitis C: a proof-of-concept phase 2 cohort study
-
A.Kohli, A.Osinusi, Z.Sims, et al. Virological response after 6 week triple drug regimens for hepatitis C: a proof-of-concept phase 2 cohort study. Lancet. 2015;385:1107–1113.
-
(2015)
Lancet
, vol.385
, pp. 1107-1113
-
-
Kohli, A.1
Osinusi, A.2
Sims, Z.3
-
65
-
-
84943230055
-
The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment
-
B.Lam, T.Jeffers, Z.Younoszai, et al. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Ther Adv Gastroenterol. 2015;8:298–312.
-
(2015)
Ther Adv Gastroenterol
, vol.8
, pp. 298-312
-
-
Lam, B.1
Jeffers, T.2
Younoszai, Z.3
-
66
-
-
84904568743
-
Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel
-
H.Günthard, J.Aberg, J.Eron, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014;312:410–425.
-
(2014)
JAMA
, vol.312
, pp. 410-425
-
-
Günthard, H.1
Aberg, J.2
Eron, J.3
-
67
-
-
84943328674
-
Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients
-
J.Dietz, S.Susser, C.Berkowski, et al. Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients. PLoS One. 2015;10:e0134395.
-
(2015)
PLoS One
, vol.10
, pp. 134395
-
-
Dietz, J.1
Susser, S.2
Berkowski, C.3
-
68
-
-
84939271310
-
The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/- ribavirin
-
C.Sarrazin, H.Dvory-Sobol, E.Svarovskaia, et al. The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/- ribavirin. J Hepatol. 2015;62(suppl):620.
-
(2015)
J Hepatol
, vol.62
, pp. 620
-
-
Sarrazin, C.1
Dvory-Sobol, H.2
Svarovskaia, E.3
-
69
-
-
84975320514
-
Successful achievement of sustained virological response to triple combination therapy containing simeprevir in two patients with chronic hepatitis C who had failed asunaprevir-daclatasvir combination therapy
-
Forthcoming
-
I.Ozeki, T.Nakajima, M.Yamaguchi, et al. Successful achievement of sustained virological response to triple combination therapy containing simeprevir in two patients with chronic hepatitis C who had failed asunaprevir-daclatasvir combination therapy. Hepatol Res. Forthcoming.
-
Hepatol Res
-
-
Ozeki, I.1
Nakajima, T.2
Yamaguchi, M.3
-
70
-
-
84975315249
-
Retreatment with sofosbuvir and simeprevir of patients with HCV GT1 or 4 who previously failed a daclatasvir-containing regimen
-
Forthcoming
-
C.Hézode, S.Chevaliez, G.Scoazec, et al. Retreatment with sofosbuvir and simeprevir of patients with HCV GT1 or 4 who previously failed a daclatasvir-containing regimen. Hepatology. Forthcoming.
-
Hepatology
-
-
Hézode, C.1
Chevaliez, S.2
Scoazec, G.3
-
71
-
-
45749088957
-
Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?
-
V.Soriano, A.Perelson, F.Zoulim. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J Antimicrob Chemother. 2008;62:1–4.
-
(2008)
J Antimicrob Chemother
, vol.62
, pp. 1-4
-
-
Soriano, V.1
Perelson, A.2
Zoulim, F.3
-
72
-
-
84926667719
-
Global origin and transmission of HCV non-structural protein 3 Q80K polymorphism
-
R.McCloskey, R.Liang, J.Joy, et al. Global origin and transmission of HCV non-structural protein 3 Q80K polymorphism. J Infect Dis. 2015;211:1288–1295.
-
(2015)
J Infect Dis
, vol.211
, pp. 1288-1295
-
-
McCloskey, R.1
Liang, R.2
Joy, J.3
-
73
-
-
84894271490
-
In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir
-
X.Tong, S.Le Pogam, L.Li, et al. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis. 2014;209:668–675.
-
(2014)
J Infect Dis
, vol.209
, pp. 668-675
-
-
Tong, X.1
Le Pogam, S.2
Li, L.3
-
74
-
-
84975314675
-
L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions
-
Forthcoming
-
E.Svarovskaia, E.Gane, H.Dvory-Sobol, et al. L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions. J Infect Dis. Forthcoming.
-
J Infect Dis
-
-
Svarovskaia, E.1
Gane, E.2
Dvory-Sobol, H.3
-
75
-
-
84884158588
-
Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3
-
E.Tapper, N.Afdhal. Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepat. 2013;20:669–677.
-
(2013)
J Viral Hepat
, vol.20
, pp. 669-677
-
-
Tapper, E.1
Afdhal, N.2
-
76
-
-
84885949784
-
Antiviral activity and resistance of HCV NS5A replication complex inhibitors
-
N.Gao. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Op Virol. 2013;5:514–520.
-
(2013)
Curr Op Virol
, vol.5
, pp. 514-520
-
-
Gao, N.1
-
77
-
-
84900992889
-
Sofosbuvir and ribavirin in HCV genotypes 2 and 3
-
S.Zeuzem, G.Dusheiko, R.Salupere, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993–2001.
-
(2014)
N Engl J Med
, vol.370
, pp. 1993-2001
-
-
Zeuzem, S.1
Dusheiko, G.2
Salupere, R.3
-
78
-
-
84975315205
-
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+)
-
Forthcoming
-
V.Leroy, P.Angus, J.P.Bronowicki, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology. Forthcoming.
-
Hepatology
-
-
Leroy, V.1
Angus, P.2
Bronowicki, J.P.3
-
79
-
-
84952909361
-
Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection
-
G.Foster, N.Afdhal, S.Roberts, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–2617.
-
(2015)
N Engl J Med
, vol.373
, pp. 2608-2617
-
-
Foster, G.1
Afdhal, N.2
Roberts, S.3
-
80
-
-
84941943566
-
HCV targeting of patients with cirrhosis
-
P.Ferenci, K.Kozbial, M.Mandorfer, et al. HCV targeting of patients with cirrhosis. J Hepatol. 2015;63:1015–1022.
-
(2015)
J Hepatol
, vol.63
, pp. 1015-1022
-
-
Ferenci, P.1
Kozbial, K.2
Mandorfer, M.3
-
81
-
-
84913537591
-
Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation
-
M.Gambato, S.Lens, M.Navasa, et al. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. J Hepatol. 2014;61(suppl 1):120–131.
-
(2014)
J Hepatol
, vol.61
, pp. 120-131
-
-
Gambato, M.1
Lens, S.2
Navasa, M.3
-
82
-
-
84975300976
-
Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
-
Forthcoming
-
G.Foster, W.Irving, M.Cheung, et al. Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. Forthcoming.
-
J Hepatol
-
-
Foster, G.1
Irving, W.2
Cheung, M.3
-
83
-
-
84932650978
-
Safety and efficacy of simeprevir/sofosbuvir in hepatitis C infected patients with compensated and decompensated cirrhosis: a matched analysis
-
V.Saxena, L.Nyberg, M.Pauly, et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C infected patients with compensated and decompensated cirrhosis: a matched analysis. Hepatology. 2015;62:715–725.
-
(2015)
Hepatology
, vol.62
, pp. 715-725
-
-
Saxena, V.1
Nyberg, L.2
Pauly, M.3
-
84
-
-
84933181270
-
Ledipasvir and sofosbuvir in patients with genotype 1 HCV and compensated cirrhosis: an integrated safety and efficacy analysis
-
K.Reddy, M.Bourlière, M.Sulkowski, et al. Ledipasvir and sofosbuvir in patients with genotype 1 HCV and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology. 2015;62:79–86.
-
(2015)
Hepatology
, vol.62
, pp. 79-86
-
-
Reddy, K.1
Bourlière, M.2
Sulkowski, M.3
-
85
-
-
84937064772
-
Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and non-cirrhotic patients with chronic hepatitis C virus genotype 1, 4 or 6 Infection: a randomized trial
-
S.Zeuzem, R.Ghalib, K.Reddy, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and non-cirrhotic patients with chronic hepatitis C virus genotype 1, 4 or 6 Infection: a randomized trial. Ann Intern Med. 2015;163:1–13.
-
(2015)
Ann Intern Med
, vol.163
, pp. 1-13
-
-
Zeuzem, S.1
Ghalib, R.2
Reddy, K.3
-
86
-
-
84975280004
-
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicenter, open-label, randomized, phase 2 study
-
Forthcoming
-
M.Manns, D.Samuel, E.Gane, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicenter, open-label, randomized, phase 2 study. Lancet Infect Dis. Forthcoming.
-
Lancet Infect Dis
-
-
Manns, M.1
Samuel, D.2
Gane, E.3
-
88
-
-
84934281205
-
Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis
-
J.Stine, N.Intagliata, N.Shah, et al. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci. 2015;60:1031–1035.
-
(2015)
Dig Dis Sci
, vol.60
, pp. 1031-1035
-
-
Stine, J.1
Intagliata, N.2
Shah, N.3
-
89
-
-
84975315219
-
Severe hepatotoxicity associated with asunaprevir and daclatasvir in chronic hepatitis
-
Forthcoming
-
S.Shibata, T.Umemura, M.Komatsu, et al. Severe hepatotoxicity associated with asunaprevir and daclatasvir in chronic hepatitis. C Hepatol. Forthcoming.
-
C Hepatol
-
-
Shibata, S.1
Umemura, T.2
Komatsu, M.3
-
90
-
-
84901036125
-
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis
-
F.Poordad, C.Hezode, R.Trinh, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–1982.
-
(2014)
N Engl J Med
, vol.370
, pp. 1973-1982
-
-
Poordad, F.1
Hezode, C.2
Trinh, R.3
-
91
-
-
84975280015
-
Liver failure in HIV-HCV coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy
-
Forthcoming
-
A.Marchan, L.Dominguez, P.Kessler, et al. Liver failure in HIV-HCV coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy. J Hepatol. Forthcoming.
-
J Hepatol
-
-
Marchan, A.1
Dominguez, L.2
Kessler, P.3
-
92
-
-
84939799650
-
Dual antiviral therapy for HIV and hepatitis C: drug interactions and side effects
-
I.Esposito, P.Labarga, P.Barreiro, et al. Dual antiviral therapy for HIV and hepatitis C: drug interactions and side effects. Expert Opin Drug Saf. 2015;14:1421–1434.
-
(2015)
Expert Opin Drug Saf
, vol.14
, pp. 1421-1434
-
-
Esposito, I.1
Labarga, P.2
Barreiro, P.3
-
93
-
-
50649112802
-
Treatment predictors of a sustained virologic response in hepatitis B and C
-
A.Kau, J.Vermehren, C.Sarrazin. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol. 2008;49:634–651.
-
(2008)
J Hepatol
, vol.49
, pp. 634-651
-
-
Kau, A.1
Vermehren, J.2
Sarrazin, C.3
-
94
-
-
78349296832
-
Modelling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with HCV and HIV
-
J.Medrano, K.Neukam, N.Rallón, et al. Modelling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with HCV and HIV. Clin Infect Dis. 2010;51:1209–1216.
-
(2010)
Clin Infect Dis
, vol.51
, pp. 1209-1216
-
-
Medrano, J.1
Neukam, K.2
Rallón, N.3
-
95
-
-
79953173221
-
Boceprevir for untreated chronic HCV genotype 1 infection
-
F.Poordad, J.McCone, B.Bacon, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206.
-
(2011)
N Engl J Med
, vol.364
, pp. 1195-1206
-
-
Poordad, F.1
McCone, J.2
Bacon, B.3
-
96
-
-
84865494240
-
Factors that predict response of patients with hepatitis C virus infection to boceprevir
-
F.Poordad, J.Bronowicki, S.Gordon, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology. 2012;143:608–618.
-
(2012)
Gastroenterology
, vol.143
, pp. 608-618
-
-
Poordad, F.1
Bronowicki, J.2
Gordon, S.3
-
98
-
-
84900326091
-
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
-
K.Kowdley, S.Gordon, K.Reddy, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–1888.
-
(2014)
N Engl J Med
, vol.370
, pp. 1879-1888
-
-
Kowdley, K.1
Gordon, S.2
Reddy, K.3
-
99
-
-
84941564098
-
A phase 3 randomized open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir plus sofosbuvir in treatment-naïve and –experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1
-
P.Kwo, N.Gitlin, R.Nahass, et al. A phase 3 randomized open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir plus sofosbuvir in treatment-naïve and –experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1. J Hepatol. 2015;62(suppl 2):270 [abstract LP14].
-
(2015)
J Hepatol
, vol.62
-
-
Kwo, P.1
Gitlin, N.2
Nahass, R.3
-
100
-
-
84898634396
-
Therapy for hepatitis C – the costs of success
-
J.Hoofnagle, A.Sherker. Therapy for hepatitis C – the costs of success. N Engl J Med. 2014;370:1552–1553.
-
(2014)
N Engl J Med
, vol.370
, pp. 1552-1553
-
-
Hoofnagle, J.1
Sherker, A.2
-
101
-
-
0242624536
-
Impact of immunosuppression on immunopathogenesis of liver damage in HCV-infected recipients following liver transplantation
-
G.McCaughan, A.Zekry. Impact of immunosuppression on immunopathogenesis of liver damage in HCV-infected recipients following liver transplantation. Liver Transpl. 2003;9(suppl):21–27.
-
(2003)
Liver Transpl
, vol.9
, pp. 21-27
-
-
McCaughan, G.1
Zekry, A.2
-
102
-
-
84970008872
-
High serum HCV-RNA in chronic hepatitis C patients coinfected with HIV despite successful antiretroviral therapy
-
Forthcoming, This article reports serum HCV-RNA levels in a large population demonstrating that greater viral loads are uniformly seen in HIV–HCV coinfected versus HCV-monoinfected individuals
-
P.Barreiro, P.Labarga, C.de Mendoza, et al. High serum HCV-RNA in chronic hepatitis C patients coinfected with HIV despite successful antiretroviral therapy. Antivir Ther. Forthcoming.• This article reports serum HCV-RNA levels in a large population demonstrating that greater viral loads are uniformly seen in HIV–HCV coinfected versus HCV-monoinfected individuals.
-
Antivir Ther
-
-
Barreiro, P.1
Labarga, P.2
de Mendoza, C.3
-
103
-
-
85027940359
-
Viral hepatitis: treating hepatitis C in injection drug users
-
V.Soriano, L.Gallego. Viral hepatitis: treating hepatitis C in injection drug users. Nat Rev Gastroenterol Hepatol. 2013;10:568–569.
-
(2013)
Nat Rev Gastroenterol Hepatol
, vol.10
, pp. 568-569
-
-
Soriano, V.1
Gallego, L.2
-
104
-
-
84895547921
-
Towards hepatitis C eradication from the HIV-infected population
-
P.Barreiro, J.V.Fernandez-Montero, C.de Mendoza, et al. Towards hepatitis C eradication from the HIV-infected population. Antivir Res. 2014;105:1–7.
-
(2014)
Antivir Res
, vol.105
, pp. 1-7
-
-
Barreiro, P.1
Fernandez-Montero, J.V.2
de Mendoza, C.3
-
105
-
-
84947614518
-
Current and evolving treatments of genotype 1 hepatitis C virus
-
S.Alqahtani, M.Sulkowski. Current and evolving treatments of genotype 1 hepatitis C virus. Gastroenterol Clin N Am. 2015;44:825–843.
-
(2015)
Gastroenterol Clin N Am
, vol.44
, pp. 825-843
-
-
Alqahtani, S.1
Sulkowski, M.2
-
106
-
-
84884531390
-
Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy
-
P.Barreiro, P.Labarga, J.V.Fernández-Montero, et al. Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy. J Clin Virol. 2013;58:391–395.
-
(2013)
J Clin Virol
, vol.58
, pp. 391-395
-
-
Barreiro, P.1
Labarga, P.2
Fernández-Montero, J.V.3
-
107
-
-
84975286079
-
Applicability of HCV RNA viral load thresholds for 8-week treatments in patients with chronic hepatitis C genotype 1 infection
-
Forthcoming
-
J.Vermehren, B.Maasoumy, R.Maan, et al. Applicability of HCV RNA viral load thresholds for 8-week treatments in patients with chronic hepatitis C genotype 1 infection. Clin Infect Dis. Forthcoming.
-
Clin Infect Dis
-
-
Vermehren, J.1
Maasoumy, B.2
Maan, R.3
-
108
-
-
84925362379
-
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease inhibitor therapy: a randomized, double-blind, phase 2 trial (SIRIUS)
-
M.Bourliere, J.Bronowicki, V.de Ledinghen, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease inhibitor therapy: a randomized, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15:397–404.
-
(2015)
Lancet Infect Dis
, vol.15
, pp. 397-404
-
-
Bourliere, M.1
Bronowicki, J.2
de Ledinghen, V.3
-
109
-
-
84952909361
-
Sofosbuvir and velpatasvir for HCV genotypes 2 and 3
-
G.Foster, N.Afdhal, S.Roberts, et al. Sofosbuvir and velpatasvir for HCV genotypes 2 and 3. N Engl J Med. 2015;373:2608–2617.
-
(2015)
N Engl J Med
, vol.373
, pp. 2608-2617
-
-
Foster, G.1
Afdhal, N.2
Roberts, S.3
-
110
-
-
84975278563
-
Hepatitis C therapeutics: pangenotypic therapeutics on the horizon
-
Boston, MA: Feb, [abstract 56]
-
K.Lacombe. Hepatitis C therapeutics: pangenotypic therapeutics on the horizon. CROI 2016. Boston, MA; 2016 Feb 22–25. [abstract 56].
-
(2016)
CROI 2016
-
-
Lacombe, K.1
-
111
-
-
84949089864
-
Avoiding treatment failures associated with HCV resistance
-
J.M.Pawlotsky. Avoiding treatment failures associated with HCV resistance. Nature Rev Gastroenterol Hepatol. 2015;12:673–674.
-
(2015)
Nature Rev Gastroenterol Hepatol
, vol.12
, pp. 673-674
-
-
Pawlotsky, J.M.1
|